Nobody left behind – help support new DAA treatments for people with hep C that is hard to treat
New Direct Acting Anti-viral treatments were funded on the Pharmaceutical Benefits Scheme (PBS) from 1 March 2016, with more becoming available on 1 May. These treatments cure 95% of people in just 12 weeks with minimal side-effects, but are not suitable for everyone with hepatitis C.
The Pharmaceutical Benefits Advisory Committee (PBAC) is soon to consider whether a new combination treatment for hep C should be made available to people in Australia living with hep C.
Zepatier is a once-daily, single tablet containing two direct-acting antiviral (DAA) drugs, grazoprevir and elbasvir, that are active against hepatitis C genotypes 1, 4 and 6 (and can also be taken with sofosbuvir to treat genotype 3). It is especially useful for people with particular conditions such as:
- people who have not responded to previous therapy,
- people with cirrhosis,
- people living with HIV and hepatitis C co-infection, and
- people with chronic kidney disease who cannot tolerate current treatments.
If approved, Zepatier would also offer interferon-free treatment for people with hepatitis C genotypes 4 and 6 for the first time.
Hepatitis NSW invites community members and healthcare workers to make a submission to the PBAC telling them why providing access to Zepatier is so important. You can have a direct impact on broadening the choice of treatments available to people in Australia living with hepatitis C.
Please download the submission guide and follow the link to make an online submission.
Submissions close 8 June 2016, so time is tight.